Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | GAPDH | P04406 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.32 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.32 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5558224 | 1.00 | TYMP (0.34) | TYMPPRMT6ADORA2AADORA2BGAPDH | |
| SCHEMBL29881527 | 1.00 | TYMP (0.34) | TYMPPRMT6ADORA2AADORA2BGAPDH | |
| SCHEMBL25727 | 0.95 | TYMP (0.33) | TYMPPRMT6ADORA2AADORA2BGAPDH | |
| SCHEMBL4620914 | 0.93 | CDK5 (0.34) | TYMP | |
| SCHEMBL211959 | 0.91 | ADORA2A (0.32) | TYMPPRMT6ADORA2AADORA2BADORA3 | |
| SCHEMBL29793195 | 0.91 | TYMP (0.33) | TYMP | |
| SCHEMBL19825361 | 0.91 | PRMT6 (0.33) | PRMT6ADORA2AADORA2BGAPDHADORA3 | |
| SCHEMBL19814045 | 0.91 | PRMT6 (0.33) | PRMT6ADORA2AADORA2BGAPDHADORA3 | |
| SCHEMBL29793002 | 0.91 | TYMP (0.33) | TYMP | |
| SCHEMBL210112 | 0.90 | ADORA2B (0.33) | PRMT6ADORA2AADORA2BADORA3PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-9885036-B2 | Double-stranded polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-02-06 | — | — | US | disclosed |
| EP-1015469-B2 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | EXIQON AS (DK) | 2015-11-18 | — | — | EP | disclosed |
| EP-2305805-B1 | DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-8153365-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2012-04-10 | — | — | US | disclosed |
| US-8080644-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-12-20 | — | — | US | disclosed |
| US-8034909-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| US-20110245327-A1 | Oligonucleotide Analogues | EXIQON A/S (DK) | 2011-10-06 | — | — | US | disclosed |
| EP-2341058-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| EP-2341057-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| US-7153954-B2 | Method for preparation of LNA phosphoramidites | SANTARIS PHARMA A/S (DK) | 2006-12-26 | — | — | US | disclosed |
| US-7034133-B2 | Locked Nucleoside Analogues is a biochemical conjugate of nucleotides; as an aptamer in specific binding of antibiotics, drugs, amino acids, peptides, enzymes, saccharides, polysaccharides; heat resistance | EXIQON A/S (DK) | 2006-04-25 | — | — | US | disclosed |
| US-20050287566-A1 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES; using an oligomer to isolate, purify, amplify, detect, identify, quantify or capture a natural or synthetic nucleic acid | QIAGEN GMBH (DE) | 2005-12-29 | — | — | US | disclosed |
| EP-1557424-A1 | Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues | Exiqon A/S (DK) | 2005-07-27 | — | — | EP | disclosed |
| EP-1015469-B1 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | EXIQON AS (DK) | 2005-04-13 | — | — | EP | disclosed |
| EP-1409497-B1 | METHOD FOR PREPARATION OF LNA PHOSPHORAMIDITES | SANTARIS PHARMA AS (DK) | 2005-01-19 | — | — | EP | disclosed |
| US-6794499-B2 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES | EXIQON A/S (DK) | 2004-09-21 | — | — | US | disclosed |
| US-6670461-B1 | Bi-, tri, or polycyclic nucleoside analogues having a \"locked\" structure capable of forming heat resistant nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. | EXIQON A/S (DK) | 2003-12-30 | — | — | US | disclosed |
| US-20030134808-A1 | Oligonucleotide analogues | WENGEL JESPER (DK) | 2003-07-17 | — | — | US | disclosed |
| US-20030032794-A1 | Method for preparation of LNA phosphoramidites | SANTARIS PHARMA A/S (DK) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032794-A1 | Method for preparation of LNA phosphoramidites | NCL, PNP, RNGTT | TYMP 9/4885PRMT6 1119/4885ADORA2A 1186/4885 |
| US-20030134808-A1 | Oligonucleotide analogues | TARBP1, DCLRE1B, ADAR | TYMP 23/4885PRMT6 4729/4885ADORA2A 696/4885 |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | TYMP 2769/4885PRMT6 2065/4885ADORA2A 693/4885 |
| US-20110245327-A1 | Oligonucleotide Analogues | POLRMT, POLM, POLN | TYMP 19/4885PRMT6 4771/4885ADORA2A 246/4885 |
| US-20050287566-A1 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES; using an oligomer to isolate, purify, amplify, detect, identify, quantify or capture a natural or synthetic nucleic acid | POLRMT, POLM, POLN | TYMP 61/4885PRMT6 4752/4885ADORA2A 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.